Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $10.14 Consensus Target Price from Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have received a consensus rating of “Hold” from the nine ratings firms that are presently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $10.14.

Several analysts recently weighed in on the stock. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 price objective on shares of Neumora Therapeutics in a research report on Tuesday, March 4th. Stifel Nicolaus downgraded Neumora Therapeutics from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $6.00 to $2.00 in a research note on Friday, March 7th. Needham & Company LLC reiterated a “buy” rating and set a $5.00 price objective on shares of Neumora Therapeutics in a research report on Tuesday, March 4th. Bank of America reduced their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Finally, HC Wainwright dropped their target price on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th.

Institutional Investors Weigh In On Neumora Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Neumora Therapeutics in the fourth quarter worth $61,000. PNC Financial Services Group Inc. acquired a new stake in Neumora Therapeutics during the fourth quarter valued at approximately $64,000. Quantbot Technologies LP bought a new stake in shares of Neumora Therapeutics in the 4th quarter valued at approximately $92,000. PEAK6 LLC acquired a new position in shares of Neumora Therapeutics in the 4th quarter worth approximately $117,000. Finally, EntryPoint Capital LLC acquired a new stake in Neumora Therapeutics in the 4th quarter valued at $135,000. 47.65% of the stock is currently owned by institutional investors.

Neumora Therapeutics Stock Performance

Shares of NMRA stock opened at $1.20 on Tuesday. The stock has a market capitalization of $194.37 million, a price-to-earnings ratio of -0.64 and a beta of 2.59. Neumora Therapeutics has a one year low of $1.12 and a one year high of $17.19. The company’s 50-day simple moving average is $1.70 and its 200-day simple moving average is $7.81.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.09. As a group, research analysts forecast that Neumora Therapeutics will post -1.61 EPS for the current year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.